GRCEHealthcare · Biotechnology

GRCE Stock Forecast: Grace Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 12 Nov 2026

$1.83

−1.61% on the day

The 2 Wall Street analysts covering Grace Therapeutics, Inc. hold a median 12-month price target of $5.85 — +219.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 52 of 100 as at 11 Nov 2026 — in the upper half.

Market cap

$39.0M

Ticker Nerd rank

52/ 100

Median analyst target

$5.85

Analysts covering

Revenue$0.0

Operating income−$2.4M

Net income−$15.8M

Free cash flow−$3.2M

Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown

Total return, dividends reinvested

+2.8%

−9.4%

YTD

−47.1%

−39.6%

From 52W high

−64.3%

From 52W low

+2.8%

$1.78

$5.13

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

GRCE stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Grace Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 11 Nov 2026

52/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals

Size

Volatility

Quality

Revisions

Growth

Value

Issuance

Momentum

Accruals (89): Reported profit is backed by cash, and the company is not expanding recklessly.

Momentum (16): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

GRCE stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on GRCE, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts

2 Buy0 Hold0 Sell

Low $3.89Median $5.85High $7.81

The green dot is the last close — the median target sits +219.6% from it.

Recent analyst actionsNewest first

Date	Firm	Action	Rating	Target
24 Apr 2026	TD Cowen	Maintains	Buy	$12 → $8.00
18 Feb 2025	HC Wainwright & Co.	Reiterates	Buy	—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

GRCE appears in the Radar on the weeks it earns a place.

Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

The AI build-out map

PDF

AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST

Performance

GRCE vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 12 Nov 2026, Grace Therapeutics, Inc. returned −39.6% against +12.0% for the S&P 500, dividends included.

GRCE vs S&P 500, last 12 monthsTotal return, rebased to 100

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

GRCE analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year

Analysts raising

Analysts cutting

Fundamentals

Grace Therapeutics, Inc. (GRCE) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: −4.0×
Price / sales: —
Price / book: 0.6×
EV / EBITDA: −2.5×

Growth & margins

Revenue growth (YoY): —
Earnings growth (YoY): —
Gross margin: —
Operating margin: 0.0%
Net margin: 0.0%

Returns & dividend

Return on equity: −36.2%
Return on assets: −10.8%
Dividend yield: 0.0%

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Grace Therapeutics, Inc. (GRCE) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

Grace Therapeutics, Inc. has a market value of $39.0M and an enterprise value of $25.6M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$20.2M.
Free cash flow in the twelve months to 30 June 2026: −$10.3M.
Shares outstanding: 16.3M.
Trailing P/E: −4.0×; forward P/E: −4.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Grace Therapeutics, Inc. employs 5 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 12 Nov 2026

Data provided by Twelve Data

Peers

GRCE vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology

Company	Market cap	TKN rank
GRCEGrace Therapeutics, Inc.	$39.0M	52
ALDXAldeyra Therapeutics, Inc.	$39.3M	51
GRDXGridAI Technologies Corp.	$39.3M	14
TVGNTevogen, Inc.	$38.5M	16
KLRSKalaris Therapeutics, Inc.	$39.8M	31
SERSerina Therapeutics, Inc.	$38.1M	17
EXOZeXoZymes, Inc.	$37.1M	12

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Grace Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest GRCE news & analysis

Grace Therapeutics Announces Second Quarter 2027 Financial Results, Provides Business Update

GlobeNewsWire · 12 Nov 2026neutral

Grace Therapeutics announced financial results and business highlights for the three months ended September 30, 2026. The company is advancing GTx-104, an injectable nimodipine formulation that completed a Phase 3 trial and is being developed for IV infusion for aSAH patients.

Why it matters — The update covers quarterly results and business developments related to GRCE’s late-stage GTx-104 program.

Grace Therapeutics Announces Participation in Upcoming Industry and Investor Events in November 2026

GlobeNewsWire · 5 Nov 2026neutral

Grace Therapeutics announced that it will participate in healthcare industry and investor conferences during November 2026. The company is advancing GTx-104, a clinical-stage injectable nimodipine formulation for IV infusion in aSAH patients.

Why it matters — The announcement provides GRCE watchers with information about the company’s scheduled industry and investor engagement.

FAQ

Frequently asked questions about GRCE stock

What is the GRCE stock price forecast for 2026-2027?

The 2 Wall Street analysts covering Grace Therapeutics, Inc. have a median 12-month price target of $5.85, with estimates ranging from $3.89 to $7.81. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is GRCE stock a buy right now?

Of the 2 analysts covering Grace Therapeutics, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Grace Therapeutics, Inc. 52 out of 100 across roughly 4,600 US stocks as at 11 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank GRCE?

As at 11 Nov 2026, Grace Therapeutics, Inc. ranks 52 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (89 of 100).

Will GRCE stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +219.6% from the last close, and Ticker Nerd's factor model ranks Grace Therapeutics, Inc. 52 out of 100 as at 11 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the GRCE stock forecast for 2030?

No analyst covering Grace Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GRCE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3.89 to $7.81 over the next 12 months.

How has GRCE stock performed over the past year?

Grace Therapeutics, Inc. returned -39.6% over the 12 months to 12 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Grace Therapeutics, Inc. do?

Grace Therapeutics, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases.

What is the latest news on GRCE?

The most recent item we track (GlobeNewsWire, 12 Nov 2026): "Grace Therapeutics Announces Second Quarter 2027 Financial Results, Provides Business Update". Grace Therapeutics announced financial results and business highlights for the three months ended September 30, 2026. The company is advancing GTx-104, an injectable nimodipine formulation that completed a Phase 3 trial and is being developed for IV infusion for aSAH patients.

Company

About Grace Therapeutics, Inc.

Grace Therapeutics, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Grace Therapeutics, Inc. currently centers on drug candidates designed to address serious neurological and pain-related conditions, including GTx-104 for aneurysmal subarachnoid hemorrhage, GTx-102 for Ataxia-Telangiectasia, and GTx-101 for postherpetic neuralgia. The company works with proprietary drug-delivery technologies aimed at improving how established molecules are formulated and administered in clinical settings. Its portfolio is positioned at the intersection of specialty pharmaceuticals and rare-disease treatment, supporting hospitals, physicians, and patients managing complex unmet medical needs. Grace Therapeutics, Inc. is headquartered in Princeton, New Jersey.

CEO Mr. Prashant Kohli · 5 employees · United States · https://www.gracetx.com